fluvoxamine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1230 54739-18-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • fluvoxamine
  • fluvoxamine maleate
  • depromel
A selective serotonin reuptake inhibitor that is used in the treatment of DEPRESSION and a variety of ANXIETY DISORDERS. Because of its high affinity at the sigma-1 receptor, the drug was evaluated whether could prevent clinical deterioration in patients with COVID-19. At the moment, there are insufficient data to recommend either for or against use of fluvoxamine for the treatment of COVID-19.
  • Molecular weight: 318.34
  • Formula: C15H21F3N2O2
  • CLOGP: 2.77
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 1
  • TPSA: 56.84
  • ALOGS: -4.64
  • ROTB: 10

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.10 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 14.87 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 2 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 13.46 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 53 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 23.50 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 31.95 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.20 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 12.50 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 5, 1994 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug interaction 344.34 18.75 243 6493 228888 63253398
Myoglobin urine present 283.86 18.75 52 6684 720 63481566
Serotonin syndrome 218.43 18.75 90 6646 28592 63453694
Toxic encephalopathy 194.88 18.75 57 6679 6522 63475764
Amylase increased 174.91 18.75 52 6684 6293 63475993
Suicide attempt 159.33 18.75 92 6644 60826 63421460
Troponin increased 158.84 18.75 54 6682 10067 63472219
Blood creatine phosphokinase increased 152.01 18.75 71 6665 30359 63451927
Intentional overdose 145.11 18.75 93 6643 74059 63408227
Blood potassium increased 131.04 18.75 55 6681 18254 63464032
Intentional self-injury 125.38 18.75 59 6677 25628 63456658
Blood lactate dehydrogenase increased 121.85 18.75 56 6680 23060 63459226
Toxicity to various agents 81.79 18.75 115 6621 247135 63235151
Neuroleptic malignant syndrome 75.62 18.75 33 6703 12023 63470263
Drug abuse 73.20 18.75 61 6675 72457 63409829
Somnolence 72.68 18.75 92 6644 178593 63303693
Alanine aminotransferase increased 68.90 18.75 69 6667 103701 63378585
Suicidal ideation 51.85 18.75 47 6689 62374 63419912
Mydriasis 50.84 18.75 25 6711 11931 63470355
Electrocardiogram QT prolonged 45.90 18.75 43 6693 59487 63422799
Sopor 43.76 18.75 28 6708 22136 63460150
Oscillopsia 42.16 18.75 8 6728 135 63482151
Drug level increased 40.67 18.75 27 6709 22709 63459577
Schizophrenia 39.91 18.75 20 6716 9932 63472354
Galactorrhoea 38.36 18.75 15 6721 4140 63478146
Overdose 35.68 18.75 52 6684 115026 63367260
Obsessive-compulsive disorder 35.18 18.75 14 6722 4046 63478240
Hypotension 33.64 18.75 83 6653 272521 63209765
Tremor 30.26 18.75 52 6684 132187 63350099
Anxiety 29.80 18.75 69 6667 217472 63264814
Extrapyramidal disorder 29.28 18.75 18 6718 13266 63469020
Completed suicide 29.12 18.75 54 6682 145619 63336667
Agitation 26.19 18.75 32 6704 59725 63422561
Restlessness 26.07 18.75 23 6713 29430 63452856
Psychotic disorder 24.61 18.75 21 6715 25691 63456595
Torsade de pointes 24.22 18.75 16 6720 13335 63468951
Alice in wonderland syndrome 23.82 18.75 4 6732 32 63482254
Drug screen false positive 23.29 18.75 7 6729 877 63481409
Akinesia 23.03 18.75 8 6728 1585 63480701
Mental disorder 22.46 18.75 20 6716 25899 63456387
Anaemia folate deficiency 21.64 18.75 5 6731 225 63482061
Personality disorder 21.32 18.75 11 6725 5800 63476486
Congestive cardiomyopathy 20.68 18.75 11 6725 6171 63476115
Dysarthria 20.57 18.75 24 6712 42687 63439599
Aspiration of gastric residual 19.63 18.75 3 6733 12 63482274
Altered state of consciousness 19.00 18.75 18 6718 25212 63457074
Miosis 18.90 18.75 11 6725 7342 63474944

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Loss of libido 211.93 22.45 55 5897 2497 34948482
Drug interaction 158.78 22.45 193 5759 225753 34725226
Apathy 153.87 22.45 54 5898 6878 34944101
Sedation 142.13 22.45 70 5882 20936 34930043
Schizophrenia 131.37 22.45 51 5901 8615 34942364
Psychotic disorder 126.44 22.45 68 5884 24384 34926595
Suicidal ideation 121.18 22.45 79 5873 40309 34910670
Serotonin syndrome 99.03 22.45 54 5898 19879 34931100
Neuroleptic malignant syndrome 76.58 22.45 44 5908 17890 34933089
Persecutory delusion 76.53 22.45 25 5927 2555 34948424
Drug level increased 75.60 22.45 47 5905 22049 34928930
Encephalitis toxic 70.92 22.45 15 5937 273 34950706
Antipsychotic drug level increased 66.64 22.45 25 5927 3840 34947139
Orthostatic hypotension 66.39 22.45 46 5906 25873 34925106
Salivary hypersecretion 65.02 22.45 31 5921 8613 34942366
Social avoidant behaviour 64.28 22.45 23 5929 3091 34947888
Delirium 62.34 22.45 55 5897 43936 34907043
Aggression 61.88 22.45 52 5900 38912 34912067
Intentional overdose 60.68 22.45 54 5898 43620 34907359
Tardive dyskinesia 60.12 22.45 26 5926 5764 34945215
Enuresis 58.64 22.45 20 5932 2333 34948646
Weight increased 57.76 22.45 75 5877 92958 34858021
Overdose 55.89 22.45 73 5879 90986 34859993
Suicide attempt 55.60 22.45 49 5903 39067 34911912
Catatonia 50.33 22.45 22 5930 5003 34945976
Obsessive-compulsive disorder 48.18 22.45 22 5930 5542 34945437
Depression 46.35 22.45 69 5883 97029 34853950
Sopor 44.51 22.45 27 5925 12109 34938870
Obesity 40.54 22.45 26 5926 12852 34938127
Completed suicide 38.83 22.45 64 5888 98104 34852875
Sexual relationship change 38.01 22.45 6 5946 17 34950962
Mental impairment 37.94 22.45 23 5929 10299 34940680
Toxicity to various agents 37.76 22.45 96 5856 200266 34750713
Cardiac dysfunction 36.26 22.45 14 5938 2324 34948655
Sexual dysfunction 33.85 22.45 18 5934 6285 34944694
Anxiety 31.74 22.45 59 5893 99369 34851610
Hanging 31.29 22.45 7 5945 167 34950812
Orgasmic sensation decreased 30.93 22.45 6 5946 69 34950910
Cyclothymic disorder 29.64 22.45 6 5946 87 34950892
Obsessive thoughts 29.37 22.45 9 5943 746 34950233
Coma scale abnormal 28.99 22.45 14 5938 3994 34946985
Respiratory fatigue 28.86 22.45 6 5946 100 34950879
Antipsychotic drug level above therapeutic 28.85 22.45 10 5942 1223 34949756
Premature ejaculation 27.55 22.45 6 5946 126 34950853
Intentional self-injury 27.41 22.45 21 5931 13750 34937229
Neonatal behavioural syndrome 27.28 22.45 6 5946 132 34950847
Motor developmental delay 26.15 22.45 8 5944 660 34950319
Hypothermia 25.00 22.45 18 5934 10730 34940249
Distributive shock 24.89 22.45 9 5943 1245 34949734
Akathisia 24.60 22.45 16 5936 8093 34942886
Genital hypoaesthesia 24.21 22.45 6 5946 225 34950754
Tic 23.87 22.45 10 5942 2048 34948931
Labelled drug-drug interaction medication error 23.81 22.45 20 5932 14919 34936060
Irritability 23.81 22.45 25 5927 24665 34926314
Somnolence 23.81 22.45 56 5896 111060 34839919
Impulsive behaviour 23.40 22.45 10 5942 2152 34948827
Brain injury 23.38 22.45 14 5938 6128 34944851
Heat stroke 23.25 22.45 8 5944 957 34950022
Bradycardia 23.11 22.45 44 5908 75374 34875605

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug interaction 407.39 17.13 382 10540 414801 79318665
Serotonin syndrome 291.65 17.13 136 10786 44891 79688575
Myoglobin urine present 242.02 17.13 49 10873 898 79732568
Intentional overdose 185.76 17.13 137 10785 105823 79627643
Suicide attempt 174.80 17.13 120 10802 82812 79650654
Toxic encephalopathy 135.31 17.13 53 10869 11387 79722079
Intentional self-injury 133.24 17.13 72 10850 32347 79701119
Troponin increased 127.14 17.13 59 10863 19196 79714270
Blood creatine phosphokinase increased 123.77 17.13 89 10833 66001 79667465
Neuroleptic malignant syndrome 121.10 17.13 64 10858 27495 79705971
Amylase increased 118.88 17.13 48 10874 11161 79722305
Loss of libido 106.88 17.13 31 10891 2654 79730812
Toxicity to various agents 105.91 17.13 199 10723 421341 79312125
Suicidal ideation 103.83 17.13 85 10837 76255 79657211
Sedation 99.70 17.13 71 10851 51824 79681642
Blood potassium increased 87.95 17.13 53 10869 29222 79704244
Drug level increased 84.92 17.13 58 10864 39593 79693873
Overdose 80.51 17.13 112 10810 184094 79549372
Psychotic disorder 80.33 17.13 57 10865 41345 79692121
Apathy 80.21 17.13 38 10884 12939 79720527
Blood lactate dehydrogenase increased 76.17 17.13 54 10868 39116 79694350
Somnolence 74.28 17.13 124 10798 238857 79494609
Sopor 72.38 17.13 49 10873 32961 79700505
Schizophrenia 71.07 17.13 37 10885 15403 79718063
Encephalitis toxic 68.02 17.13 14 10908 279 79733187
Obsessive-compulsive disorder 64.97 17.13 26 10896 5901 79727565
Catatonia 64.62 17.13 29 10893 8727 79724739
Completed suicide 62.74 17.13 117 10805 245650 79487816
Salivary hypersecretion 62.37 17.13 33 10889 14191 79719275
Drug abuse 60.96 17.13 92 10830 162599 79570867
Enuresis 60.87 17.13 21 10901 3155 79730311
Aggression 59.50 17.13 52 10870 50906 79682560
Anxiety 51.00 17.13 108 10814 248404 79485062
Tremor 48.50 17.13 85 10837 169998 79563468
Antipsychotic drug level increased 48.04 17.13 21 10901 5936 79727530
Orthostatic hypotension 44.03 17.13 46 10876 56118 79677348
Agitation 42.56 17.13 60 10862 99655 79633811
Tardive dyskinesia 42.07 17.13 23 10899 10548 79722918
Galactorrhoea 39.98 17.13 16 10906 3630 79729836
Akathisia 39.79 17.13 24 10898 13235 79720231
Delirium 37.72 17.13 52 10870 84575 79648891
Oscillopsia 37.13 17.13 8 10914 200 79733266
Extrapyramidal disorder 36.70 17.13 28 10894 22651 79710815
Obsessive thoughts 36.04 17.13 11 10911 1121 79732345
Mydriasis 35.85 17.13 25 10897 17618 79715848
Dyspnoea 34.60 17.13 40 10882 856985 78876481
Hanging 33.26 17.13 7 10915 156 79733310
Sexual relationship change 33.08 17.13 5 10917 13 79733453
Pain 32.77 17.13 29 10893 703773 79029693
Mental impairment 31.90 17.13 24 10898 19012 79714454
Cyclothymic disorder 31.23 17.13 7 10915 211 79733255
Arthralgia 31.17 17.13 20 10902 571783 79161683
Electrocardiogram QT prolonged 30.85 17.13 49 10873 90337 79643129
Alanine aminotransferase increased 30.28 17.13 68 10854 162502 79570964
Distributive shock 30.19 17.13 12 10910 2675 79730791
Irritability 29.24 17.13 32 10890 41112 79692354
Cardiac dysfunction 28.34 17.13 13 10909 4111 79729355
Orgasmic sensation decreased 27.50 17.13 5 10917 50 79733416
Semen volume decreased 26.22 17.13 5 10917 66 79733400
Premature ejaculation 26.15 17.13 5 10917 67 79733399
Rhabdomyolysis 26.13 17.13 49 10873 103082 79630384
Labelled drug-drug interaction medication error 25.99 17.13 25 10897 27625 79705841
Antipsychotic drug level above therapeutic 25.87 17.13 10 10912 2070 79731396
Parkinsonism 25.79 17.13 20 10902 16564 79716902
Gaze palsy 25.56 17.13 11 10911 2994 79730472
Psychomotor skills impaired 25.39 17.13 13 10909 5224 79728242
Respiratory fatigue 24.57 17.13 6 10916 264 79733202
Activation syndrome 24.25 17.13 6 10916 279 79733187
Mania 24.10 17.13 20 10902 18240 79715226
Drug reaction with eosinophilia and systemic symptoms 23.55 17.13 36 10886 64208 79669258
Sexual dysfunction 23.16 17.13 14 10908 7749 79725717
Restlessness 22.89 17.13 30 10892 46462 79687004
Myoclonus 22.29 17.13 23 10899 27637 79705829
Bradycardia 22.28 17.13 54 10868 135503 79597963
Hallucination 22.04 17.13 41 10881 85704 79647762
Coma scale abnormal 21.72 17.13 14 10908 8664 79724802
Febrile neutropenia 21.61 17.13 3 10919 230996 79502470
Alice in wonderland syndrome 21.49 17.13 4 10918 46 79733420
Inappropriate antidiuretic hormone secretion 21.42 17.13 22 10900 26291 79707175
Altered state of consciousness 21.15 17.13 28 10894 43794 79689672
Genital hypoaesthesia 21.04 17.13 5 10917 196 79733270
Hypotension 20.99 17.13 117 10805 440200 79293266
Acanthosis nigricans 20.97 17.13 5 10917 199 79733267
Hyperprolactinaemia 20.92 17.13 11 10911 4665 79728801
Weight increased 20.74 17.13 84 10838 277302 79456164
Brain injury 20.37 17.13 15 10907 11502 79721964
Diarrhoea 20.32 17.13 58 10864 880431 78853035
Drug screen false positive 19.97 17.13 7 10915 1102 79732364
Impulsive behaviour 19.49 17.13 9 10913 2891 79730575
Anaemia folate deficiency 18.90 17.13 5 10917 304 79733162
Aspiration of gastric residual 18.86 17.13 3 10919 12 79733454
Hypothermia 18.48 17.13 19 10903 22727 79710739
Akinesia 18.35 17.13 9 10913 3303 79730163
Delusion 18.32 17.13 18 10904 20405 79713061
Negativism 17.68 17.13 6 10916 857 79732609
Self-injurious ideation 17.55 17.13 9 10913 3629 79729837
Depressed level of consciousness 17.50 17.13 40 10882 96612 79636854

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N06AB08 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTIDEPRESSANTS
Selective serotonin reuptake inhibitors
FDA MoA N0000000109 Serotonin Uptake Inhibitors
CHEBI has role CHEBI:35469 antidepressants
CHEBI has role CHEBI:35474 anti-anxiety agents
CHEBI has role CHEBI:50949 SSRI
FDA EPC N0000175696 Serotonin Reuptake Inhibitor
MeSH PA D014151 Anti-Anxiety Agents
MeSH PA D000928 Antidepressive Agents
MeSH PA D018687 Antidepressive Agents, Second-Generation
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D065609 Cytochrome P-450 CYP1A2 Inhibitors
MeSH PA D065689 Cytochrome P-450 CYP2C19 Inhibitors
MeSH PA D065607 Cytochrome P-450 Enzyme Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D065606 Metabolic Side Effects of Drugs and Substances
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D014179 Neurotransmitter Uptake Inhibitors
MeSH PA D011619 Psychotropic Drugs
MeSH PA D017367 Selective Serotonin Reuptake Inhibitors
MeSH PA D018490 Serotonin Agents
MeSH PA D014149 Tranquilizing Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Social phobia indication 25501002 DOID:11257
Obsessive-compulsive disorder indication 191736004 DOID:10933
Depressive disorder off-label use 35489007
Posttraumatic stress disorder off-label use 47505003 DOID:2055
Bipolar affective disorder, current episode depression off-label use 191627008 DOID:3312
Suicidal thoughts contraindication 6471006
Bipolar disorder contraindication 13746004 DOID:3312
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Upper gastrointestinal hemorrhage contraindication 37372002
Syndrome of inappropriate vasopressin secretion contraindication 55004003 DOID:3401
Blood coagulation disorder contraindication 64779008 DOID:1247
Epilepsy contraindication 84757009 DOID:1826
Hyponatremia contraindication 89627008
Mania contraindication 231494001
Hypomania contraindication 231496004
Disease of liver contraindication 235856003 DOID:409
Serotonin syndrome contraindication 371089000
Breastfeeding (mother) contraindication 413712001
Poor metabolizer due to cytochrome p450 CYP2D6 variant contraindication 423629005
Smokes tobacco daily contraindication 449868002




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.36 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sodium-dependent serotonin transporter Transporter INHIBITOR Ki 8.51 WOMBAT-PK CHEMBL
Sodium-dependent noradrenaline transporter Transporter Ki 5.95 PDSP
Sodium-dependent dopamine transporter Transporter Ki 8.84 CHEMBL
Cytochrome P450 1A2 Enzyme Ki 5.07 WOMBAT-PK
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 7.44 CHEMBL
Sodium-dependent serotonin transporter Transporter INHIBITOR Ki 8.19 IUPHAR
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 7.44 CHEMBL
Sigma intracellular receptor 2 Unclassified Ki 5.07 CHEMBL

External reference:

IDSource
4023976 VUID
N0000021981 NUI
D00824 KEGG_DRUG
61718-82-9 SECONDARY_CAS_RN
4020892 VANDF
4023976 VANDF
C0085228 UMLSCUI
CHEBI:5138 CHEBI
FVX PDB_CHEM_ID
CHEMBL814 ChEMBL_ID
DB00176 DRUGBANK_ID
CHEMBL1409 ChEMBL_ID
D016666 MESH_DESCRIPTOR_UI
5324346 PUBCHEM_CID
7189 IUPHAR_LIGAND_ID
3879 INN_ID
O4L1XPO44W UNII
203143 RXNORM
40916 MMSL
4758 MMSL
d03804 MMSL
003633 NDDF
003634 NDDF
116522003 SNOMEDCT_US
372905008 SNOMEDCT_US
96213009 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 0228-2848 CAPSULE, EXTENDED RELEASE 100 mg ORAL ANDA 21 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 0228-2848 CAPSULE, EXTENDED RELEASE 100 mg ORAL ANDA 21 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 0228-2849 CAPSULE, EXTENDED RELEASE 150 mg ORAL ANDA 21 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 0228-2849 CAPSULE, EXTENDED RELEASE 150 mg ORAL ANDA 21 sections
Fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 0832-1670 TABLET, FILM COATED 25 mg ORAL ANDA 34 sections
Fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 0832-1670 TABLET, FILM COATED 25 mg ORAL ANDA 34 sections
Fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 0832-1671 TABLET, FILM COATED 50 mg ORAL ANDA 34 sections
Fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 0832-1671 TABLET, FILM COATED 50 mg ORAL ANDA 34 sections
Fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 0832-1672 TABLET, FILM COATED 100 mg ORAL ANDA 34 sections
Fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 0832-1672 TABLET, FILM COATED 100 mg ORAL ANDA 34 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 10370-175 CAPSULE, EXTENDED RELEASE 100 mg ORAL ANDA 30 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 10370-175 CAPSULE, EXTENDED RELEASE 100 mg ORAL ANDA 30 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 10370-176 CAPSULE, EXTENDED RELEASE 150 mg ORAL ANDA 30 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 10370-176 CAPSULE, EXTENDED RELEASE 150 mg ORAL ANDA 30 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 16590-270 TABLET 25 mg ORAL NDA 11 sections
fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 33261-683 TABLET, COATED 50 mg ORAL NDA AUTHORIZED GENERIC 31 sections
fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 50090-5988 TABLET, COATED 100 mg ORAL NDA authorized generic 31 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 60505-0164 TABLET 25 mg ORAL ANDA 32 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 60505-0165 TABLET 50 mg ORAL ANDA 32 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 60505-0166 TABLET 100 mg ORAL ANDA 32 sections
fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 62559-158 TABLET, COATED 25 mg ORAL NDA authorized generic 31 sections
fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 62559-158 TABLET, COATED 25 mg ORAL NDA authorized generic 31 sections
fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 62559-159 TABLET, COATED 50 mg ORAL NDA authorized generic 31 sections
fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 62559-159 TABLET, COATED 50 mg ORAL NDA authorized generic 31 sections
fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 62559-160 TABLET, COATED 100 mg ORAL NDA authorized generic 31 sections
fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 62559-160 TABLET, COATED 100 mg ORAL NDA authorized generic 31 sections
fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 63629-8018 TABLET, COATED 25 mg ORAL NDA authorized generic 31 sections
fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 68071-2337 TABLET, COATED 50 mg ORAL NDA authorized generic 31 sections
fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 68151-0637 TABLET, COATED 50 mg ORAL NDA authorized generic 31 sections
fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 68788-7219 TABLET, COATED 100 mg ORAL NDA authorized generic 31 sections